WBR0673

Revision as of 01:20, 7 November 2013 by Rim Halaby (talk | contribs) (Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Pharmacology |SubCategory=Endocrine |MainCategory=Pharmacology |SubCategory=Endocrine |MainCategory=...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
 
Author [[PageAuthor::Rim Halaby, M.D. [1]]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Endocrine
Prompt [[Prompt::A 52 year old obese man, with a past medical history significant for hypertension, dyslipidemia, diverticulosis, and chronic kidney disease and a past surgical history of cholecystectomy, presents to the physician's office for his annual check-up. Routine work-up shows HbA1c = 7.5%. The physician decides he wants to start oral anti diabetic therapy to treat the patient's condition. Which of the following medications must be avoided in the patient's condition?]]
Answer A AnswerA::Pioglitazone
Answer A Explanation AnswerAExp::Pioglitazone is a thiazolidinedione (TZD). It is not contraindicated in chronic kidney disease. It is contraindicated in heart failure.
Answer B AnswerB::Pramlintide
Answer B Explanation AnswerBExp::Pramlintide is an amylin analog that decreases glucagon. It is not contraindicated in renal failure.
Answer C AnswerC::Metformin
Answer C Explanation AnswerCExp::Metformin is a biguanide that is commonly used as a first line therapy for type 2 diabetes mellitus. It is contraindicated in renal failure and in patients among the age of 80 years. It has been associated, in rare cases, with lactic acidosis.
Answer D AnswerD::Exenatide
Answer D Explanation AnswerDExp::Exenatide is a GLP-1 analog that increases insulin and decreases the release of glucagon. It is associated with GI distress and pancreatitis.
Answer E AnswerE::Glimepiride
Answer E Explanation [[AnswerEExp::Glimepiride is a second generation sulfonylurea (SU). It is associated with hypoglycemia because SU are secretagogues, not sensitizers. It is not contraindicated in renal failure. Glipidize, on the other hand, is contraindicated in renal failure; whereas glyburide is contraindicated in liver failure.]]
Right Answer RightAnswer::C
Explanation [[Explanation::The patient is newly diagnosed with type 2 diabetes mellitus, with an elevated HbA1c > 6.4 % and requires oral anti-diabetic pharmacologic therapy. Generally, metformin, a biguanide that acts as a sensitizer, is considered a first line therapy for patients with type 2 diabetes mellitus. However, it is contraindicated in renal failure and may not be initiated in patients above 80 years of age. In rare occasions also, it has been associated with lactic acidosis. Since the patient is known to have chronic kidney disease, metformin is thus contraindicated and must be avoided.

Educational Objective: Metformin is contraindicated in renal failure
Educational Objective:
References: ]]

Approved Approved::No
Keyword WBRKeyword::metformin, WBRKeyword::diabetes, WBRKeyword::mellitus, WBRKeyword::type, WBRKeyword::2, WBRKeyword::contraindication, WBRKeyword::contraindicated, WBRKeyword::renal, WBRKeyword::failure, WBRKeyword::chronic, WBRKeyword::kidney disease, WBRKeyword::oral, WBRKeyword::antidiabetic, WBRKeyword::therapy
Linked Question Linked::
Order in Linked Questions LinkedOrder::